Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study

Headache

Volumn 45, Issue 4, 2005, Pages 315-324

  Dodick, David W ^a   Mauskop, Alexander ^b   Elkind, Arthur H ^c   DeGryse, Ronald ^d   Brin, Mitchell F ^d   Silberstein, Stephen D ^e  

^a MAYO CLINIC   (United States)

^b New York Headache Center   (United States)

^c Elkind Headache Center   (United States)

^d ALLERGAN INC   (United States)

^e JEFFERSON HEADACHE CENTER   (United States)

Author keywords

Botulinum toxin type A; Chronic daily headache; Double blind; Placebo control; Prophylaxis

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; ANAMNESIS; ARTICLE; CHRONIC DAILY HEADACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPESTHESIA; INJURY; MAJOR CLINICAL STUDY; MALE; MUSCLE HYPERTONIA; MUSCLE WEAKNESS; NECK PAIN; OPEN STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PTOSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SHOULDER PAIN; SKIN MANIFESTATION; TREATMENT OUTCOME;

ADULT; BOTULINUM TOXIN TYPE A; DOUBLE-BLIND METHOD; FEMALE; HEADACHE DISORDERS; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 17244371697     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.05068.x     Document Type: Article

References (39)

1. Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol. 2000;13:277-283.
2. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache. 1998;38:497-506.
3. Castillo J, Munoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache. 1999;39:190-196.
4. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology. 2000;54:314-319.
5. Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep. 2001;5:529-536.
6. Lanteri-Minet M, Auray JP, El Hasnaoui A, et al. Prevalence and description of chronic daily headache in the general population in France. Pain. 2003;102:143-149.
7. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache. 1987;27:102-106.
8. Guitera V, Munoz P, Castillo J, Pascual J. Quality of life in chronic daily headache: a study in a general population. Neurology. 2002;58:1062-1065.
9. D'Amico D, Usai S, Grazzi L, et al. Quality of life and disability in primary chronic daily headaches. Neurol Sci. 2003;24(suppl 2):S97-S100.
10. Wang SJ, Fuh JL, Lu SR, Juang KD. Quality of life differs among headache diagnoses: analysis of SF-36 survey in 901 headache patients. Pain. 2001;89:285-292.
11. Ondo W, Vuong K, Derman H. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia. 2004;24:60-65.
12. rd, Cantrell DT, Winner P, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42:470-482.
13. rd, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache. 1994;34:497-502.
14. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003;23:820-824.
15. Spira PJ, Beran RG. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61:1753-1759.
16. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965-973.
17. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281-286.
18. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17:103-108.
19. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490-495.
20. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58:885-894.
21. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41:638-645.
22. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43(suppl 1):S16-S24.
23. Zalvan C, Bentsianov B, Gonzalez-Yanes O, Blitzer A. Noncosmetic uses of botulinum toxin. Dermatol Clin. 2004;22:187-195.
24. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type a in pain management. Headache. 2003;43(suppl 1):9-15.
25. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125-133.
26. Durham PL, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35-42; discussion 42-43.
27. Oshinsky ML, Pozo-Rosich P, Luo J, Hyman S, Silberstein S. Botulinum toxin type A blocks sensitization of neurons in the trigeminal nucleus caudalis. Cephalalgia. 2004;24:781.
28. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol. 2004;55:27-36.
29. Silberstein S, Mathew N, Saper J, Jenkins S, Group FtBMCR. Botulinum toxin type A as a migraine preventive treatment. Headache. 2000;40:445-450.
30. Barrientos N, Chana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain. 2003;4:146-151.
31. Tepper S, Bigal M, Sheftell F, Rapoport A. Botulinum neurotoxin type a in the preventative treatment of refractory headache: a review of 100 consecutive cases. Headache. 2004;44:794-800.
32. Troost BT. Botulinum toxin type A (BOTOX®) in the treatment of migraine and other headaches. Expert Rev Neurotherapeutics. 2004;41:27-31.
33. Blumenfeld A. Botulinum toxin type a as an effective prophylactic treatment in primary headache disorders. Headache. 2003;43:853-860.
34. Mathew N, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:293-307.
35. Couch JR Jr. Placebo effect and clinical trials in migraine therapy. Neuroepidemiology. 1987;6:178-185.
36. Rapoport AM, Bigal ME, Volcy M, Sheftell FD, Feleppa M, Tepper SJ. Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases. Headache. 2003;43:482-489.
37. Naumann M. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20:981-990.
38. DEPAKOTE® [package insert]. Abbott Park, IL: Abbott Laboratories, Inc.; 2003.
39. TOPAMAX® [package insert]. Raritan, NJ: OrthoMcNeil Pharmaceutical, Inc.; 2004.